Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/107810
Title:
Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.
Authors:
Gurney, H; De Campos, E S; Dodwell, David J; Kamthan, A; Thatcher, Nick
Abstract:
42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10/42 patients (23.8%) and stable disease in 25/42 (59.5%). The Karnofsky performance status (KP) improved in 10/42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity.
Affiliation:
Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, U.K.
Citation:
Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer. 1991, 27 (5):565-8 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
1991
URI:
http://hdl.handle.net/10541/107810
DOI:
10.1016/0277-5379(91)90218-3
PubMed ID:
1647182
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorGurney, Hen
dc.contributor.authorDe Campos, E Sen
dc.contributor.authorDodwell, David Jen
dc.contributor.authorKamthan, Aen
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-07-16T15:22:34Z-
dc.date.available2010-07-16T15:22:34Z-
dc.date.issued1991-
dc.identifier.citationIfosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer. 1991, 27 (5):565-8 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid1647182-
dc.identifier.doi10.1016/0277-5379(91)90218-3-
dc.identifier.urihttp://hdl.handle.net/10541/107810-
dc.description.abstract42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10/42 patients (23.8%) and stable disease in 25/42 (59.5%). The Karnofsky performance status (KP) improved in 10/42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCancer Metastasisen
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshLung Neoplasms-
dc.subject.meshMiddle Aged-
dc.subject.meshMitomycins-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshPrognosis-
dc.titleIfosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, U.K.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.